Testing telitacicept vs cyclophosphamide for lupus lung disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus.
- You must have a lung condition called interstitial lung disease, confirmed by a CT scan.
- Your breathing test results must show at least 60% of normal lung function for FEV1/FVC, and a diffusion capacity of 40% or higher.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the trial.
- You cannot have severe liver, kidney, or blood problems, a history of bleeding risks, or be on strong blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new biologic drug called telitacicept for people with systemic lupus erythematosus (SLE). It aims to see how safe and effective the drug is and may offer a new treatment option for lupus.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests if a combination of three drugs (azithromycin, hydroxychloroquine, and prednisone) can help people with a genetic form of lung scarring. The goal is to see if these medicines calm the immune system and slow down the disease.
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.